ClinicalTrials.gg
CompletedNCT05577702Updated Feb 9, 2026Results posted

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

A Phase 2 interventional study of Tislelizumab and Ociperlimab in Non Small Cell Lung Cancer, sponsored by BeiGene. Completed at 14 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 22 under way, 2 of them phase 3. tislelizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
11th of 41
121 · median 39
Started
2023
with 5 others
Phase 2
26 of 41
17 open now
Registered
17th of 41
by date
Lead sponsor
10 of 41
BeiGene

Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by enrollment, is one of 6 that started in 2023, is one of 26 in phase 2, and was the 17th registered.

Carcinoma, Non-Small-Cell Lung

7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study was conducted to evaluate the preliminary effectiveness and safety of treatment with tislelizumab alone and in combination with other investigational agents prior to surgery (neoadjuvant treatment) in adults with non-small cell lung cancer (NSCLC) that is able to be removed by surgery.

Read the detailed description

This is a randomized, open-label, multicenter, Phase 2, umbrella study to evaluate the preliminary efficacy, safety, and pharmacodynamics of tislelizumab as monotherapy and in combination with investigational agents as neoadjuvant treatment in Chinese participants with resectable Stage II to IIIA NSCLC. The study is designed with the flexibility of adding treatment arms as new treatments become available or discontinuing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, and of modifying the participant population.

The study consisted of a neoadjuvant treatment phase (2 - 4 cycles of treatment), a surgery phase and a follow-up phase.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Performance Status (ECOG PS) of 0 or 1
  • confirmed Stage II-IIIA NSCLC (per the Eighth American Joint Committee on Cancer/Union Internationale Contre le Cancer [NSCLC] staging system)
  • Evaluation by an attending thoracic surgeon to confirm eligibility for an R0 resection with curative intent
  • Adequate hematologic and organ function, defined by protocol-specified laboratory test results, obtained ≤ 7 days before randomization
  • Provide formalin-fixed paraffin-embedded block (preferred) or at least 15 freshly cut unstained FFPE slides of the primary tumor for biomarker evaluation during screening

Exclusion criteria

Exclusion Criteria:

  • Any prior antineoplastic therapy(ies) for current lung cancer (eg, radiotherapy, targeted therapies, ablation, or other systemic or local antineoplastic treatment)
  • Prior therapy with an , anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-cell immunoglobulin and ITIM domain (TIGIT), anti-lymphocyte activation gene-3 (LAG-3), or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Has mixed small cell lung cancer
  • Participants with large cell neuroendocrine carcinoma (LCNEC)
  • The presence of locally advanced unresectable NSCLC regardless of stage or disease
  • Known epidermal growth factor receptor (EGFR) sensitizing mutations and/or anaplastic lymphoma kinase (ALK) rearrangement

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Arm 1A: Tislelizumab Monotherapy

    Participants with tumor programmed death protein ligand-1 (PD-L1) expression ≥ 50% received 200 mg tislelizumab intravenously once every 3 weeks for 2-4 cycles followed by surgical removal of the tumor.

    Drug: Tislelizumab

  • Experimental
    Arm 1B: Tislelizumab + Ociperlimab

    Participants with tumor PD-L1 expression ≥ 50% received 200 mg tislelizumab and 900 mg ociperlimab intravenously once every 3 weeks for 2-4 cycles followed by surgical removal of the tumor.

    Drug: Tislelizumab · Drug: Ociperlimab

  • Experimental
    Arm 1C: Alcestobart + Tislelizumab

    Participants with tumor PD-L1 expression ≥ 50% received 200 mg tislelizumab and 600 mg alcestobart intravenously once every 3 weeks for 2-4 cycles followed by surgical removal of the tumor.

    Drug: Tislelizumab · Drug: Alcestobart

  • Experimental
    Arm 2A: Tislelizumab and Chemotherapy

    Participants with tumor PD-L1 expression \< 50% received 200 mg tislelizumab and chemotherapy consisting of cisplatin or carboplatin with either pemetrexed or paclitaxel administered intravenously once every 3 weeks for 2-4 cycles followed by surgical removal of the tumor.

    Drug: Tislelizumab · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed · Drug: Paclitaxel

  • Experimental
    Arm 2C: Alcestobart + Tislelizumab + Chemotherapy

    Participants with tumor PD-L1 expression \< 50% received 200 mg tislelizumab, 600 mg alcestobart and chemotherapy consisting of cisplatin or carboplatin with either pemetrexed or paclitaxel administered intravenously once every 3 weeks for 2-4 cycles followed by surgical removal of the tumor.

    Drug: Tislelizumab · Drug: Alcestobart · Drug: Cisplatin · Drug: Carboplatin · Drug: Pemetrexed · Drug: Paclitaxel

Interventions

  • Administered as an intravenous infusion once every 3 weeks

    Also known as: BGB-A317, Tevimbra

  • Administered as an intravenous infusion once every 3 weeks

    Also known as: BGB-A1217

  • Administered as an intravenous infusion once every 3 weeks

    Also known as: LBL-007

  • 75 mg/m\^2 administered as an intravenous infusion once every 3 weeks

  • Administered as an intravenous infusion once every 3 weeks at an area under the curve (AUC) of 5 mg/mL/min

  • 500 mg/m\^2 administered as an intravenous infusion once every 3 weeks in participants with non-squamous NSCLC

  • 175 mg/m\^2 administered as an intravenous infusion once every 3 weeks in participants with squamous NSCLC

06

What researchers measure

Primary outcomes

  1. Major Pathological Response (MPR) Rate

    Tumor tissue and lymph node tissue obtained from surgical resection were sent to a central laboratory according to study pathology manuals for pathological response analysis. MPR rate is defined as the percentage of participants with ≤ 10% residual viable tumor in the resected primary tumor and all resected lymph nodes as assessed by blinded independent pathology review (BIPR). Participants without surgery or pathological results were considered non-responders.

    Time frame: At the time of surgery, approximately Week 16

Secondary outcomes

  1. Pathological Complete Response (pCR)

    Pathological complete response is defined as the percentage of participants with absence of residual tumor in the resected primary tumor and all resected lymph nodes as assessed by the BIPR. Participants without surgery or pathological results were considered as non-responders.

    Time frame: At the time of surgery, approximately Week 16

  2. Event-free Survival (EFS)

    EFS is defined as the time from randomization until any of the following events, whichever occurred first: radiographic disease progression that precludes definitive surgery, local or distant recurrence as assessed by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause. Local recurrence is defined as recurrence in the ipsilateral thorax (lymph node or lung on the same side as Baseline location) including lung parenchyma, bronchial stump, main trachea, hilum or mediastinal lymph nodes (including subcarinal lymph nodes), pleura and chest wall diagnosed by radiological examination and/or histopathological confirmation. Distant recurrence (metastasis) is defined as spread of disease beyond the area of the ipsilateral thorax (including contralateral area and other organs) diagnosed by radiological examination and/or histopathological confirmation. Median EFS was estimated using Kaplan-Meier methodology.

    Time frame: From randomization until the end of study, maximum time on study was 22 months in Substudy 1 and 13 months in Substudy 2.

  3. Event-free Survival Rate

    Event-free survival rate is defined as the percentage of participants with none of the following events: radiographic disease progression that precludes definitive surgery, local or distant recurrence as assessed by investigator per RECIST v1.1, or death due to any cause. Local recurrence is defined as recurrence in the ipsilateral thorax (lymph node or lung on the same side as Baseline location) including lung parenchyma, bronchial stump, main trachea, hilum or mediastinal lymph nodes (including subcarinal lymph nodes), pleura and chest wall diagnosed by radiological examination and/or histopathological confirmation. Distant recurrence (metastasis) is defined as spread of disease beyond the area of the ipsilateral thorax (including contralateral area and other organs) diagnosed by radiological examination and/or histopathological confirmation. EFS rates were estimated using the Kaplan-Meier method with the corresponding 95% confidence interval constructed using Greenwood's formula.

    Time frame: 12 months and 24 months after randomization

  4. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using Kaplan-Meier methodology.

    Time frame: From randomization until the end of study, maximum time on study was 22 months in Substudy 1 and 13 months in Substudy 2.

  5. Overall Survival Rate

    Overall survival rate is defined as the percentage of participants who were still alive at the analysis time points. OS rates were estimated using the Kaplan-Meier method with the corresponding 95% confidence interval constructed using Greenwood's formula.

    Time frame: 12 months and 24 months after randomization

  6. Disease-free Survival (DFS)

    DFS is defined as the time from the first date of no disease (ie, participants who underwent margin-negative \[R0\] resection) to local or distant recurrence, as assessed by the investigator according to RECIST v1.1, or death due to any cause, whichever occurred first. Median DFS was estimated using Kaplan-Meier methodology.

    Time frame: From randomization until the end of study, maximum time on study was 22 months in Substudy 1 and 13 months in Substudy 2.

  7. Disease-free Survival Rate

    Disease-free survival rate is defined as the percentage of participants with none of the following events: Local or distant recurrence as assessed by the investigator per RECIST v1.1, or death due to any cause. Local recurrence is defined as recurrence in the ipsilateral thorax (lymph node or lung on the same side as Baseline location) including lung parenchyma, bronchial stump, main trachea, hilum or mediastinal lymph nodes (including subcarinal lymph nodes), pleura and chest wall diagnosed by radiological examination and/or histopathological confirmation. Distant recurrence (metastasis) is defined as spread of disease beyond the area of the ipsilateral thorax (including contralateral area and other organs) diagnosed by radiological examination and/or histopathological confirmation. DFS rates were estimated using the Kaplan-Meier method with the corresponding 95% confidence interval constructed using Greenwood's formula.

    Time frame: 12 months and 24 months after randomization

  8. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator or sponsor based on medical judgement (eg, may have jeopardized the participant or may require medical/surgical intervention to prevent one of the outcomes listed above). Immune-mediated adverse events (imAEs) are autoimmune-mediated complications that may develop in response to immunotherapeutic agents. Immune-mediated AEs were collected from the date of first dose of study drug to 90 days after the last dose of study drug, regardless of whether the participant started a new anticancer therapy or prespecified adjuvant treatment. imAEs were identified by the investigator based on a standard process defined in the Protocol.

    Time frame: From first dose of study drug until 30 days after last dose or new anticancer treatment, whichever occurred first, or up to 90 days after the last dose for imAEs; maximum duration of treatment was 14 weeks.

  9. Feasibility of Surgery

    Feasibility of surgery was assessed by the number of participants who underwent surgical resection (surgery) within 6 weeks of last dose of study drug, had delayed or canceled surgery, the approach of surgery, duration of surgery (see next outcome measure) ,and the number of participants who underwent an exploratory thoracotomy, a surgical procedure in which a cut is made between the ribs to see and reach the lungs or other organs in the chest or thorax. Exploratory thoracotomy was not counted as surgery.

    Time frame: At the time of surgery, approximately Week 16

  10. Duration of Surgery

    The duration of surgery is defined as the time interval from the start of the surgical procedure to its completion.

    Time frame: Approximately Week 16

07

Results

Posted Feb 9, 2026

Participant flow

This study enrolled 121 participants at study sites in China.

Participant flow — Overall Study
MilestoneArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
Started2020202041
Treated2020201940
Completed00000
Not completed2020202041
Withdrew: Study ended by sponsor1917191638
Withdrew: Death12132
Withdrew: Withdrawal by subject01011

Outcome measures

PrimaryMajor Pathological Response (MPR) Rate

Tumor tissue and lymph node tissue obtained from surgical resection were sent to a central laboratory according to study pathology manuals for pathological response analysis. MPR rate is defined as the percentage of participants with ≤ 10% residual viable tumor in the resected primary tumor and all resected lymph nodes as assessed by blinded independent pathology review (BIPR). Participants without surgery or pathological results were considered non-responders.

Time frame:
At the time of surgery, approximately Week 16
Reported as:
Number · percentage of participants
Major Pathological Response (MPR) Rate
percentage of participantsArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
Major Pathological Response (MPR) Rate45.0 (23.1 to 68.5)50.0 (27.2 to 72.8)40.0 (19.1 to 63.9)55.0 (31.5 to 76.9)34.1 (20.1 to 50.6)
Statistical analysis
  • Arm 1A: Tislelizumab Monotherapy vs Arm 1B: Tislelizumab + Ociperlimab · Odds ratio (or): 1.22 · 95% CI 0.35 to 4.24Mantel-Haenszel common odds ratio was estimated along with its 95% confidence interval (CI) constructed by a normal approximation of log odds ratio and the Robins, Breslow, and Greenland variance estimate without stratification.
  • Arm 1A: Tislelizumab Monotherapy vs Arm 1C: Alcestobart + Tislelizumab · Odds ratio (or): 0.81 · 95% CI 0.23 to 2.86Mantel-Haenszel common odds ratio was estimated along with its 95% CI constructed by a normal approximation of log odds ratio and the Robins, Breslow, and Greenland variance estimate without stratification.
  • Arm 2A: Tislelizumab and Chemotherapy vs Arm 2C: Alcestobart + Tislelizumab + Chemotherapy · Odds ratio (or): 0.42 · 95% CI 0.14 to 1.26Mantel-Haenszel common odds ratio was estimated along with its 95% CI constructed by a normal approximation of log odds ratio and the Robins, Breslow, and Greenland variance estimate without stratification.
SecondaryPathological Complete Response (pCR)

Pathological complete response is defined as the percentage of participants with absence of residual tumor in the resected primary tumor and all resected lymph nodes as assessed by the BIPR. Participants without surgery or pathological results were considered as non-responders.

Time frame:
At the time of surgery, approximately Week 16
Reported as:
Number · percentage of participants
Pathological Complete Response (pCR)
percentage of participantsArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
Pathological Complete Response (pCR)30.0 (11.9 to 54.3)30.0 (11.9 to 54.3)40.0 (19.1 to 63.9)35.0 (15.4 to 59.2)17.1 (7.2 to 32.1)
Statistical analysis
  • Arm 1A: Tislelizumab Monotherapy vs Arm 1B: Tislelizumab + Ociperlimab · Odds ratio (or): 1.00 · 95% CI 0.26 to 3.87Mantel-Haenszel common odds ratio was estimated along with its 95% CI constructed by a normal approximation of log odds ratio and the Robins, Breslow, and Greenland variance estimate without stratification.
  • Arm 1A: Tislelizumab Monotherapy vs Arm 1C: Alcestobart + Tislelizumab · Odds ratio (or): 1.56 · 95% CI 0.42 to 5.76Mantel-Haenszel common odds ratio was estimated along with its 95% CI constructed by a normal approximation of log odds ratio and the Robins, Breslow, and Greenland variance estimate without stratification.
  • Arm 2A: Tislelizumab and Chemotherapy vs Arm 2C: Alcestobart + Tislelizumab + Chemotherapy · Odds ratio (or): 0.38 · 95% CI 0.11 to 1.30Mantel-Haenszel common odds ratio was estimated along with its 95% CI constructed by a normal approximation of log odds ratio and the Robins, Breslow, and Greenland variance estimate without stratification.
SecondaryEvent-free Survival (EFS)

EFS is defined as the time from randomization until any of the following events, whichever occurred first: radiographic disease progression that precludes definitive surgery, local or distant recurrence as assessed by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause. Local recurrence is defined as recurrence in the ipsilateral thorax (lymph node or lung on the same side as Baseline location) including lung parenchyma, bronchial stump, main trachea, hilum or mediastinal lymph nodes (including subcarinal lymph nodes), pleura and chest wall diagnosed by radiological examination and/or histopathological confirmation. Distant recurrence (metastasis) is defined as spread of disease beyond the area of the ipsilateral thorax (including contralateral area and other organs) diagnosed by radiological examination and/or histopathological confirmation. Median EFS was estimated using Kaplan-Meier methodology.

Time frame:
From randomization until the end of study, maximum time on study was 22 months in Substudy 1 and 13 months in Substudy 2.
Reported as:
Median · months
Event-free Survival (EFS)
monthsArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
Event-free Survival (EFS)NA (10.3 to NA)NA (3.7 to NA)11.4 (11.4 to NA)11.6 (7.9 to NA)NA (10.9 to NA)
Statistical analysis
  • Arm 1A: Tislelizumab Monotherapy vs Arm 1B: Tislelizumab + Ociperlimab · Hazard ratio (hr): 2.54 · 95% CI 0.46 to 13.94Hazard ratio and 95% CIs were estimated using a Cox regression model.
  • Arm 1A: Tislelizumab Monotherapy vs Arm 1C: Alcestobart + Tislelizumab · Hazard ratio (hr): 2.26 · 95% CI 0.37 to 13.75Hazard ratio and 95% CIs were estimated using a Cox regression model.
  • Arm 2A: Tislelizumab and Chemotherapy vs Arm 2C: Alcestobart + Tislelizumab + Chemotherapy · Hazard ratio (hr): 1.00 · 95% CI 0.28 to 3.52Hazard ratio and 95% CIs were estimated using a Cox regression model.
SecondaryEvent-free Survival Rate

Event-free survival rate is defined as the percentage of participants with none of the following events: radiographic disease progression that precludes definitive surgery, local or distant recurrence as assessed by investigator per RECIST v1.1, or death due to any cause. Local recurrence is defined as recurrence in the ipsilateral thorax (lymph node or lung on the same side as Baseline location) including lung parenchyma, bronchial stump, main trachea, hilum or mediastinal lymph nodes (including subcarinal lymph nodes), pleura and chest wall diagnosed by radiological examination and/or histopathological confirmation. Distant recurrence (metastasis) is defined as spread of disease beyond the area of the ipsilateral thorax (including contralateral area and other organs) diagnosed by radiological examination and/or histopathological confirmation. EFS rates were estimated using the Kaplan-Meier method with the corresponding 95% confidence interval constructed using Greenwood's formula.

Time frame:
12 months and 24 months after randomization
Reported as:
Number · percentage of participants
Event-free Survival Rate
percentage of participantsArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
12 months75.3 (24.5 to 94.4)60.0 (17.8 to 86.0)44.0 (1.1 to 86.1)0.0 (NA to NA)50.5 (15.0 to 78.2)
24 monthsNA (NA to NA)NA (NA to NA)NA (NA to NA)0.0 (NA to NA)NA (NA to NA)
SecondaryOverall Survival (OS)

OS is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using Kaplan-Meier methodology.

Time frame:
From randomization until the end of study, maximum time on study was 22 months in Substudy 1 and 13 months in Substudy 2.
Reported as:
Median · months
Overall Survival (OS)
monthsArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
Overall Survival (OS)NA (NA to NA)NA (NA to NA)NA (11.4 to NA)NA (11.6 to NA)NA (NA to NA)
Statistical analysis
  • Arm 1A: Tislelizumab Monotherapy vs Arm 1B: Tislelizumab + Ociperlimab · Hazard ratio (hr): 2.29 · 95% CI 0.21 to 25.30Hazard ratio and 95% CIs were estimated using a Cox regression model.
  • Arm 1A: Tislelizumab Monotherapy vs Arm 1C: Alcestobart + Tislelizumab · Hazard ratio (hr): 0.99 · 95% CI 0.06 to 15.89Hazard ratio and 95% CIs were estimated using a Cox regression model.
  • Arm 2A: Tislelizumab and Chemotherapy vs Arm 2C: Alcestobart + Tislelizumab + Chemotherapy · Hazard ratio (hr): 0.29 · 95% CI 0.05 to 1.71Hazard ratio and 95% CIs were estimated using a Cox regression model.
SecondaryOverall Survival Rate

Overall survival rate is defined as the percentage of participants who were still alive at the analysis time points. OS rates were estimated using the Kaplan-Meier method with the corresponding 95% confidence interval constructed using Greenwood's formula.

Time frame:
12 months and 24 months after randomization
Reported as:
Number · percentage of participants
Overall Survival Rate
percentage of participantsArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
12 months91.7 (53.9 to 98.8)89.7 (64.8 to 97.3)90.0 (47.3 to 98.5)58.6 (8.4 to 89.2)94.9 (81.2 to 98.7)
24 monthsNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryDisease-free Survival (DFS)

DFS is defined as the time from the first date of no disease (ie, participants who underwent margin-negative \[R0\] resection) to local or distant recurrence, as assessed by the investigator according to RECIST v1.1, or death due to any cause, whichever occurred first. Median DFS was estimated using Kaplan-Meier methodology.

Time frame:
From randomization until the end of study, maximum time on study was 22 months in Substudy 1 and 13 months in Substudy 2.
Reported as:
Median · months
Disease-free Survival (DFS)
monthsArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
Disease-free Survival (DFS)NA (8.4 to NA)NA (8.0 to NA)NA (8.8 to NA)8.7 (4.0 to NA)NA (9.0 to NA)
Statistical analysis
  • Arm 1A: Tislelizumab Monotherapy vs Arm 1B: Tislelizumab + Ociperlimab · Hazard ratio (hr): 2.88 · 95% CI 0.26 to 32.37Hazard ratio and 95% CIs were estimated using a Cox regression model.
  • Arm 1A: Tislelizumab Monotherapy vs Arm 1C: Alcestobart + Tislelizumab · Hazard ratio (hr): 1.73 · 95% CI 0.11 to 27.89Hazard ratio and 95% CIs were estimated using a Cox regression model.
  • Arm 2A: Tislelizumab and Chemotherapy vs Arm 2C: Alcestobart + Tislelizumab + Chemotherapy · Hazard ratio (hr): 0.78 · 95% CI 0.19 to 3.27Hazard ratio and 95% CIs were estimated using a Cox regression model.
SecondaryDisease-free Survival Rate

Disease-free survival rate is defined as the percentage of participants with none of the following events: Local or distant recurrence as assessed by the investigator per RECIST v1.1, or death due to any cause. Local recurrence is defined as recurrence in the ipsilateral thorax (lymph node or lung on the same side as Baseline location) including lung parenchyma, bronchial stump, main trachea, hilum or mediastinal lymph nodes (including subcarinal lymph nodes), pleura and chest wall diagnosed by radiological examination and/or histopathological confirmation. Distant recurrence (metastasis) is defined as spread of disease beyond the area of the ipsilateral thorax (including contralateral area and other organs) diagnosed by radiological examination and/or histopathological confirmation. DFS rates were estimated using the Kaplan-Meier method with the corresponding 95% confidence interval constructed using Greenwood's formula.

Time frame:
12 months and 24 months after randomization
Reported as:
Number · percentage of participants
Disease-free Survival Rate
percentage of participantsArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
12 months75.0 (12.8 to 96.1)60.6 (7.5 to 90.8)50.0 (0.6 to 91.0)0.0 (NA to NA)NA (NA to NA)
24 monthsNA (NA to NA)NA (NA to NA)NA (NA to NA)0.0 (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator or sponsor based on medical judgement (eg, may have jeopardized the participant or may require medical/surgical intervention to prevent one of the outcomes listed above). Immune-mediated adverse events (imAEs) are autoimmune-mediated complications that may develop in response to immunotherapeutic agents. Immune-mediated AEs were collected from the date of first dose of study drug to 90 days after the last dose of study drug, regardless of whether the participant started a new anticancer therapy or prespecified adjuvant treatment. imAEs were identified by the investigator based on a standard process defined in the Protocol.

Time frame:
From first dose of study drug until 30 days after last dose or new anticancer treatment, whichever occurred first, or up to 90 days after the last dose for imAEs; maximum duration of treatment was 14 weeks.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
Any TEAE714151939
Serious adverse events032213
Immune-mediated AEs063217
SecondaryFeasibility of Surgery

Feasibility of surgery was assessed by the number of participants who underwent surgical resection (surgery) within 6 weeks of last dose of study drug, had delayed or canceled surgery, the approach of surgery, duration of surgery (see next outcome measure) ,and the number of participants who underwent an exploratory thoracotomy, a surgical procedure in which a cut is made between the ribs to see and reach the lungs or other organs in the chest or thorax. Exploratory thoracotomy was not counted as surgery.

Time frame:
At the time of surgery, approximately Week 16
Reported as:
Count of participants · Participants
Feasibility of Surgery
ParticipantsArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
Underwent Surgery1614121731
Received open surgery45649
Received minimally invasive surgery12961322
Received Exploratory Thoracotomy10010
Delayed Surgery73328
No Surgery or Exploratory Thoracotomy36819
SecondaryDuration of Surgery

The duration of surgery is defined as the time interval from the start of the surgical procedure to its completion.

Time frame:
Approximately Week 16
Reported as:
Median · hours
Duration of Surgery
hoursArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
Duration of Surgery3.33 (2.5 to 5.3)3.50 (2.3 to 5.3)3.39 (2.3 to 8.7)4.30 (2.7 to 8.0)4.05 (2.0 to 6.6)

Adverse events

Collected over Deaths were collected from randomization up to the end of study; maximum time on study was 22 months in Substudy 1 and 13 months in Substudy 2. Adverse events were collected from first dose of study drug until 30 days after last dose or new anticancer treatment, whichever occurred first, or up to 90 days after the last dose for imAEs; maximum duration of treatment was 14 weeks.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1A: Tislelizumab Monotherapy1/20 (5%)0/20 (0%)7/20 (35%)
Arm 1B: Tislelizumab + Ociperlimab2/20 (10%)3/20 (15%)14/20 (70%)
Arm 1C: Alcestobart + Tislelizumab1/20 (5%)2/20 (10%)14/20 (70%)
Arm 2A: Tislelizumab and Chemotherapy3/20 (15%)2/19 (10.5%)19/19 (100%)
Arm 2C: Alcestobart + Tislelizumab + Chemotherapy2/41 (4.9%)13/40 (32.5%)38/40 (95%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
PneumoniaInfections and infestations0/200/200/201/191/40
HypokalaemiaMetabolism and nutrition disorders0/200/200/201/190/40
ThrombocytosisBlood and lymphatic system disorders0/200/201/200/190/40
Myocardial injuryCardiac disorders0/201/200/200/190/40
HyperthyroidismEndocrine disorders0/201/200/200/190/40
Subarachnoid haemorrhageNervous system disorders0/201/200/200/190/40
Immune-mediated dermatitisSkin and subcutaneous tissue disorders0/200/201/200/190/40
AnaemiaBlood and lymphatic system disorders0/200/200/200/191/40
Febrile neutropeniaBlood and lymphatic system disorders0/200/200/200/191/40
LeukopeniaBlood and lymphatic system disorders0/200/200/200/191/40
Most frequent other events
Showing 10 of 118
Most frequent other events
EventArm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + Chemotherapy
Neutrophil count decreasedInvestigations2/200/200/2016/1927/40
White blood cell count decreasedInvestigations2/200/200/2012/1920/40
AnaemiaBlood and lymphatic system disorders1/203/204/2010/1923/40
NauseaGastrointestinal disorders0/201/201/207/197/40
Aspartate aminotransferase increasedInvestigations0/203/204/207/1910/40
LeukopeniaBlood and lymphatic system disorders0/200/200/206/1914/40
Platelet count decreasedInvestigations1/200/200/206/197/40
Decreased appetiteMetabolism and nutrition disorders0/201/201/203/1911/40
Alanine aminotransferase increasedInvestigations0/202/204/205/1910/40
AlopeciaSkin and subcutaneous tissue disorders0/200/200/204/1910/40

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + ChemotherapyTotal
Mean63.5 ± 6.6863.1 ± 6.7862.7 ± 8.0361.0 ± 6.8661.9 ± 9.7662.3 ± 8.03
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + ChemotherapyTotal
Female21331019
Male1819171731102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + ChemotherapyTotal
Hispanic or Latino000000
Not Hispanic or Latino2020202041121
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + ChemotherapyTotal
American Indian or Alaska Native000000
Asian2020202041121
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White000000
More than one race000000
Unknown or Not Reported000000
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Arm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + ChemotherapyTotal
0 (Fully Active)97892255
1 (Ambulatory with Restricted Activities)111312111966
Smoking Status
Smoking Status(Participants)Arm 1A: Tislelizumab MonotherapyArm 1B: Tislelizumab + OciperlimabArm 1C: Alcestobart + TislelizumabArm 2A: Tislelizumab and ChemotherapyArm 2C: Alcestobart + Tislelizumab + ChemotherapyTotal
Current3142515
Former151512152279
Never24431427
08

Study locations

14 sites
  • The First Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui 241001, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • The First Affiliated Hospital of Guangzhou Medical Universitydatansha Hospital)
    Guangzhou, Guangdong 510140, China
  • The Tumor Hospital Affiliated to Guangxi Medical University
    Nanning, Guangxi 530021, China
  • Anyang Cancer Hospital
    Anyang, Henan 455001, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • The First Affiliated Hospital of Nanchang University Branch Xianghu
    Nanchang, Jiangxi 332000, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200025, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 200433, China
  • Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital)
    Ningbo, Zhejiang 315000, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Begene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. Beigene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for Beigene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Dec 2024, 21 months.

Results were first posted in Feb 2026, 1 year 1 month after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 21 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2022
First posted
Oct 13, 2022
StartActual
Mar 8, 2023
Primary completionActual
Dec 13, 2024
CompletionActual
Jan 23, 2025
Results first posted
Feb 9, 2026
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05577702
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Oct 13, 2022
Start date
Mar 8, 2023
Primary completion
Dec 13, 2024
Completion
Jan 23, 2025
Results posted
Feb 9, 2026
Last update
Feb 9, 2026

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion